The earnings call reflects significant progress in clinical trials and strong cost management but is tempered by challenges in capital raising and dependency on partnerships for funding. The positive outcomes in the OVATION 2 study and rapid activation of the OVATION 3 trial are promising, although financial and listing compliance issues pose notable risks.

Company Guidance -

Q3 2025

In the second quarter 2025 financial results conference call for IMUNON, guidance was provided on the company's significant progress in developing IMNN-001, a gene-mediated IL-12 therapy for ovarian cancer. The OVATION 2 study demonstrated that patients receiving IMNN-001 plus standard chemotherapy had a 13-month increase in overall survival compared to standard care alone, with a hazard ratio of 0.69, a 45% improvement. Using PARP inhibitors in maintenance therapy further improved outcomes, with median overall survival not yet reached in the IMNN-001 arm versus 37 months in the control arm, yielding a hazard ratio of 0.38. IMUNON's Phase III pivotal study, OVATION 3, commenced swiftly, activating three sites and enrolling the first patient within 15 weeks, surpassing the industry average of 28 weeks. The company anticipates expanding enrollment to 500 patients or focusing on a 250-patient HRD-positive subgroup, with the potential for FDA approval. Financially, IMUNON reported a net loss of $2.7 million for Q2 2025, with operating expenses significantly reduced, and post-quarter cash inflows of over $3 million. The company is pursuing partnerships and equity to fund OVATION 3, emphasizing minimizing shareholder dilution and enhancing shareholder value through a 15% stock dividend.

Positive Results from OVATION 2 Study

IMNN-001 combined with standard chemotherapy showed a median overall survival increase of 13 months (46 months vs. 33 months), a 45% improvement, with a hazard ratio of 0.69.

Rapid Phase III Trial Activation

OVATION 3 Phase III trial was activated in 15 weeks, nearly half the industry benchmark time of 28 weeks, demonstrating agility and strong interest from investigators.

Strong Financial Management

R&D expenses decreased significantly from $2.8 million to $1.2 million, and G&A expenses fell from $2.2 million to $1.5 million year-over-year, reflecting cost management.

Innovative Financing Strategy

Implemented a 15% stock dividend to enhance shareholder value and minimize dilution, along with securing $3 million through warrant exercises and ATM sales.

Interest from Global Investigators

There is a notable interest from global investigators to participate in OVATION 3, driven by positive Phase II data and presentations at major conferences.

Imunon (IMNN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMNN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-2.02 / -	-4.435	―	―	―
Aug 05, 2025	2025 (Q2)	-4.14 / -1.87	-6.652	71.89% (+4.78)	―
May 12, 2025	2025 (Q1)	-4.57 / -3.65	-6.783	46.16% (+3.13)	―
Feb 27, 2025	2024 (Q4)	-4.67 / -3.26	-6.522	50.00% (+3.26)	―
Nov 07, 2024	2024 (Q3)	-5.06 / -4.43	-4.826	8.10% (+0.39)	―
Aug 14, 2024	2024 (Q2)	-7.04 / -6.65	-7.957	16.40% (+1.30)	―
May 13, 2024	2024 (Q1)	-7.39 / -6.78	-8.87	23.53% (+2.09)	―
Mar 28, 2024	2023 (Q4)	-7.65 / -6.52	-19.174	65.99% (+12.65)	―
Nov 14, 2023	2023 (Q3)	-8.61 / -4.83	-11.348	57.47% (+6.52)	―
Aug 10, 2023	2023 (Q2)	-9.20 / -7.96	-11.348	29.88% (+3.39)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMNN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$8.00	$7.62	-4.75%
May 12, 2025	$10.43	$10.64	+2.01%
Feb 27, 2025	$10.49	$10.56	+0.67%
Nov 07, 2024	$12.22	$10.72	-12.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Imunon (IMNN) report earnings?

Imunon (IMNN) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is Imunon (IMNN) earnings time?

Imunon (IMNN) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMNN EPS forecast?

IMNN EPS forecast for the fiscal quarter 2025 (Q3) is -2.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing